Retinoic acid improves defective TLR9/RP105-induced immune responses in common variable immunodeficiency-derived B cells

Journal of Immunology

Volumn 191, Issue 7, 2013, Pages 3624-3633

  Indrevær, Randi L ^a   Holm, Kristine L ^a   Aukrust, Pål ^a,b   Osnes, Liv T ^b   Naderi, Elin H ^a   Fevang, Børre ^a,b   Blomhoff, Heidi K ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

DEAMINASE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M; INTERLEUKIN 10; PROTEIN RP105; RETINOIC ACID; RETINOL; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL PROLIFERATION; CELL STIMULATION; CELLULAR SECRETION; CLINICAL ARTICLE; COMMON VARIABLE IMMUNODEFICIENCY; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ASSOCIATION; ENZYME INDUCTION; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; IMMUNOLOGICAL PARAMETERS; IMMUNOTHERAPY; INFECTION SENSITIVITY; MALE; PRIORITY JOURNAL; RETINOL DEFICIENCY;

ADULT; AGED; ANTIBODY FORMATION; ANTIGENS, CD; ANTIGENS, CD38; B-LYMPHOCYTES; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; CELL PROLIFERATION; COMMON VARIABLE IMMUNODEFICIENCY; FEMALE; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-10; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PLASMA CELLS; RECEPTORS, RETINOIC ACID; REPRESSOR PROTEINS; TOLL-LIKE RECEPTOR 9; TRETINOIN; YOUNG ADULT;

EID: 84885104524     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300213     Document Type: Article

References (38)

1. Cunningham-Rundles, C. 2010. How I treat common variable immune deficiency. Blood 116:7-15.
2. Resnick, E. S., E. L. Moshier, J. H. Godbold, and C. Cunningham-Rundles. 2012. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood 119:1650-1657.
3. Cunningham-Rundles, C., and C. Bodian. 1999. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin. Immunol. 92:34-48.
4. Salzer, U., and B. Grimbacher. 2006. Common variable immunodeficiency: The power of co-stimulation. Semin. Immunol. 18:337-346.
5. Borte, S., Q. Pan-Hammarstrom, C. Liu, U. Sack, M. Borte, U. Wagner, D. Graf, and L. Hammarstrom. 2009. Interleukin-21 restores immunoglobulin production ex vivo in patients with common variable immunodeficiency and selective IgA deficiency. Blood 114:4089-4098.
6. Semba, R. D. 1998. The role of vitamin A and related retinoids in immune function. Nutr. Rev. 56:S38-S48.
7. Blomhoff, R., and H. K. Blomhoff. 2006. Overview of retinoid metabolism and function. J. Neurobiol. 66:606-630.
8. Ertesvag, A., N. Engedal, S. Naderi, and H. K. Blomhoff. 2002. Retinoic acid stimulates the cell cycle machinery in normal T cells: involvement of retinoic acid receptor-mediated IL-2 secretion. J. Immunol. 169:5555-5563.
9. Ertesvag, A., H. C. Aasheim, S. Naderi, and H. K. Blomhoff. 2007. Vitamin A potentiates CpG-mediated memory B-cell proliferation and differentiation: involvement of early activation of p38MAPK. Blood 109:3865-3872.
10. Blomhoff, H. K., E. B. Smeland, B. Erikstein, A. M. Rasmussen, B. Skrede, C. Skjønsberg, and R. Blomhoff. 1992. Vitamin A is a key regulator for cell growth, cytokine production, and differentiation in normal B cells. J. Biol. Chem. 267:23988-23992.
11. Naderi, S., and H. K. Blomhoff. 1999. Retinoic acid prevents phosphorylation of pRB in normal human B lymphocytes: regulation of cyclin E, cyclin A, and p21 (Cip1). Blood 94:1348-1358.
12. Eriksen, A. B., R. L. Indrevær, K. L. Holm, J. Landskron, and H. K. Blomhoff. 2012. TLR9-signaling is required for turning retinoic acid into a potent stimulator of RP105 (CD180)-mediated proliferation and IgG synthesis in human memory B cells. Cell. Immunol. 279:87-95.
13. Peng, S. L. 2005. Signaling in B cells via Toll-like receptors. Curr. Opin. Immunol. 17:230-236.
14. Krieg, A. M., A. K. Yi, S. Matson, T. J. Waldschmidt, G. A. Bishop, R. Teasdale, G. A. Koretzky, and D. M. Klinman. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546-549.
15. Cunningham-Rundles, C., L. Radigan, A. K. Knight, L. Zhang, L. Bauer, and A. Nakazawa. 2006. TLR9 activation is defective in common variable immune deficiency. J. Immunol. 176:1978-1987.
16. Yu, J. E., A. K. Knight, L. Radigan, T. U. Marron, L. Zhang, S. Sanchez-Ramon, and C. Cunningham-Rundles. 2009. Toll-like receptor 7 and 9 defects in common variable immunodeficiency. J. Allergy Clin. Immunol. 124:349-356, 356. e1-3.
17. Clemente, A., J. Pons, N. Matamoros, J. Iglesias, and J. M. Ferrer. 2011. B cells from common variable immunodeficiency patients fail to differentiate to antibody secreting cells in response to TLR9 ligand (CpG-ODN) or anti-CD40+IL21. Cell. Immunol. 268:9-15.
18. Yamazaki, K., T. Yamazaki, S. Taki, K. Miyake, T. Hayashi, H. D. Ochs, and K. Agematsu. 2010. Potentiation of TLR9 responses for human näive B-cell growth through RP105 signaling. Clin. Immunol. 135:125-136.
19. Miyake, K., Y. Yamashita, Y. Hitoshi, K. Takatsu, and M. Kimoto. 1994. Murine B cell proliferation and protection from apoptosis with an antibody against a 105-kD molecule: unresponsiveness of X-linked immunodeficient B cells. J. Exp. Med. 180:1217-1224.
20. Chaplin, J. W., S. Kasahara, E. A. Clark, and J. A. Ledbetter. 2011. Anti-CD180 (RP105) activates B cells to rapidly produce polyclonal Ig via a T cell and MyD88-independent pathway. J. Immunol. 187:4199-4209.
21. Aukrust, P., F. Müller, T. Ueland, A. M. Svardal, R. K. Berge, and S. S. Frøland. 2000. Decreased vitamin A levels in common variable immunodeficiency: vitamin A supplementation in vivo enhances immunoglobulin production and downregulates inflammatory responses. Eur. J. Clin. Invest. 30:252-259.
22. Kilic, S. S., E. Y. Kezer, Y. O. Ilcol, T. Yakut, S. Aydin, and I. H. Ulus. 2005. Vitamin a deficiency in patients with common variable immunodeficiency. J. Clin. Immunol. 25:275-280.
23. International Union of Immunological Societies. 1999. Primary immunodeficiency diseases. Report of an IUIS Scientific Committee. Clin. Exp. Immunol. 118(Suppl. 1):1-28.
24. Funderud, S., B. Erikstein, H. C. Asheim, K. Nustad, T. Stokke, H. K. Blomhoff, H. Holte, and E. B. Smeland. 1990. Functional properties of CD19+ B lymphocytes positively selected from buffy coats by immunomagnetic separation. Eur. J. Immunol. 20:201-206.
25. Escobar, D., J. Pons, A. Clemente, J. Iglesias, V. Regueiro, J. A. Bengoechea, N. Matamoros, and J. M. Ferrer. 2010. Defective B cell response to TLR9 ligand (CpG-ODN), Streptococcus pneumoniae and Haemophilus influenzae extracts in common variable immunodeficiency patients. Cell. Immunol. 262:105-111.
26. Yu, J. E., L. Zhang, L. Radigan, S. Sanchez-Ramon, and C. Cunningham-Rundles. 2012. TLR-mediated B cell defects and IFN-a in common variable immunodeficiency. J. Clin. Immunol. 32:50-60.
27. Cunningham-Rundles, C. 2012. Human B cell defects in perspective. Immunol. Res. 54:227-232.
28. Radominska-Pandya, A., G. Chen, P. J. Czernik, J. M. Little, V. M. Samokyszyn, C. A. Carter, and G.D. Nowak. 2000. Direct interaction of all-trans-retinoic acid with protein kinase C (PKC). Implications for PKC signaling and cancer therapy. J. Biol. Chem. 275:22324-22330.
29. Ochoa, W. F., A. Torrecillas, I. Fita, N. Verdaguer, S. Corbalán-García, and J. C. Gomez-Fernandez. 2003. Retinoic acid binds to the C2-domain of protein kinase C (alpha). Biochemistry 42:8774-8779.
30. Gardulf, A., V. Andersen, J. Björkander, D. Ericson, S. S. Frøland, R. Gustafson, L. Hammarström, M. B. Jacobsen, E. Jonsson, G. Möller, et al. 1995. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 345:365-369.
31. Capolunghi, F., M. M. Rosado, M. Sinibaldi, A. Aranburu, and R. Carsetti. 2013. Why do we need IgM memory B cells? Immunol. Lett. 152:114-120.
32. Holm, A. M., P. Aukrust, E. M. Aandahl, F. Müller, K. Taskén, and S. S. Frøland. 2003. Impaired secretion of IL-10 by T cells from patients with common variable immunodeficiency-involvement of protein kinase A type I. J. Immunol. 170:5772-5777.
33. Punnonen, J., L. Kainulainen, O. Ruuskanen, J. Nikoskelainen, and H. Arvilommi. 1997. IL-4 synergizes with IL-10 and anti-CD40 MoAbs to induce B-cell differentiation in patients with common variable immunodeficiency. Scand. J. Immunol. 45:203-212.
34. Mauri, C., and A. Bosma. 2012. Immune regulatory function of B cells. Annu. Rev. Immunol. 30:221-241.
35. Sánchez-Ramón, S., L. Radigan, J. E. Yu, S. Bard, and C. Cunningham-Rundles. 2008. Memory B cells in common variable immunodeficiency: clinical associations and sex differences. Clin. Immunol. 128:314-321.
36. Krieg, A. M. 2012. CpG still rocks! Update on an accidental drug. Nucleic Acid Ther. 22:77-89.
37. Blomhoff, R., B. Skrede, and K. R. Norum. 1990. Uptake of chylomicron remnant retinyl ester via the low density lipoprotein receptor: implications for the role of vitamin A as a possible preventive for some forms of cancer. J. Intern. Med. 228:207-210.
38. Saxon, A., B. Keld, J. Braun, A. Dotson, and N. Sidell. 1993. Long-term administration of 13-cis retinoic acid in common variable immunodeficiency: circulating interleukin-6 levels, B-cell surface molecule display, and in vitro and in vivo B-cell antibody production. Immunology 80:477-487.